RecruitingNCT04026360
Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis
Sponsor
Insel Gruppe AG, University Hospital Bern
Enrollment
500 participants
Start Date
Jul 1, 2011
Study Type
OBSERVATIONAL
Conditions
Summary
This study collects data on microbiological factors and lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess their interaction on the lung growth and lung development of infants and children with Cystic Fibrosis (CF).
Eligibility
Min Age: 0 YearsMax Age: 18 Years
Inclusion Criteria3
- Infants with a confirmed diagnosis of CF by NBS
- Age <=18 years
- Written informed consent by patient and/or parent
Exclusion Criteria6
- Need for respiratory support for more than three days
- Severe malformations or known diseases other than CF
- Maternal drug abuse
- Known severe maternal disease
- Severe Problems of communication
- Pacemaker, continuous glucose monitor
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERno intervention
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04026360